Document is current
Any future updates will be listed below
-
Authors
Andersson, Peder http://orcid.org/0000-0001-8261-9613
Johnsson, Jesper
Björnsson, Ola
Cronberg, Tobias
Hassager, Christian
Zetterberg, Henrik
Stammet, Pascal
Undén, Johan
Kjaergaard, Jesper
Friberg, Hans
Blennow, Kaj
Lilja, Gisela
Wise, Matt P.
Dankiewicz, Josef
Nielsen, Niklas
Frigyesi, Attila
-
Funding
Funding for this research was provided by:
Royal Physiographic Society of Lund
Stig and Ragna Gorthon Foundation (2019-2589, 2018-1474 and 2017-1390)
Thelma Zoega Foundation (TZ2017-0062)
VO FoU Skånevård Sund
The European regional Development Fund throug the Interreg IV A OKS program
Region Skåne
The Swedish Research Council (2018-02532, 2107-00915, 134281, 296161, 286321)
The European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
AD Strategic Fund and the Alzheimer´s Association (ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C)
The European Union´s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie gran agreement (860197 (MIRIADE))
The UK Dementia Research Institute at UCL
The Swedish Alzheimer Foundation (AF-742881)
Hjärnfonden (FO2017-0243)
The Swedish state under the agreement between the Swedish government and the County Councils (AFLGBG-715986)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
Governmental funding of clinical research within the NHS (2019:YF0053)
Hjärt-Lungfonden (20090275)
Arbetsmarknadens försäkringsaktiebolag, AFA-Insurance Foundation (100001)
Regional Research Support, Region Skåne
Governmental funding of clinical research within the Swedish NHS (M2010/1837, M2010/1641, 353301)
Krapperup Foundation
Thure Carlsson Foundation
Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for Medical Research
Skånes universitetssjukhus
TrygFonden
The European Clinical Research Infrastructure Network
Lund University
- License Information
-
More Information
Article History
Received: 18 December 2020
Accepted: 10 February 2021
First Online: 25 February 2021
Ethics approval and consent to participate
: The TTM-trial protocol was approved by ethics committees in the following institutions: St George Hospital, Sydney, Australia; North Shore Hospital, Sydney, Australia; Liverpool Hospital, Sydney, Australia; The George Institute of Global Health, Sydney, Australia; General University Hospital in Prague, Prague, Czech Republic; The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Ospedale Universitario di Cattinara, Trieste, Italy; Santa Maria degli Angeli Hospital, Pordenone, Italy; San Martino, Italy; National ethics committee on research, Luxembourg; Amsterdam Medical Centre, Amsterdam, the Netherlands; Leeuwarden Hospital, Leeuwarden, the Netherlands; Rijnstaate Hospital, Arnhem, the Netherlands; Onze Lieuwe Vrouwe Gasthuis, Amsterdam, the Netherlands; Oslo University Hospital, Oslo, Norway; Haukeland University Hospital, Bergen, Norway; Helsingborg Hospital, Helsingborg, Sweden; Karlstad Hospital, Karlstad, Sweden; Kungälv Hospital, Kungälv, Sweden; Linköping University Hospital, Linköping, Sweden; Skåne University Hospital, Lund, Sweden; Skåne University Hospital, Malmö, Sweden; Norra Älvsborgs Län Hospital, Sweden; Vrinnevi Hospital, Norrköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Örebro University Hospital, Örebro, Sweden; Geneva University Hospital, Geneva, Switzerland; Hospital St.Gallen, St. Gallen, Switzerland; Hospital La Chaux de Fonds, Switzerland; University Hospital of Wales, Cardiff, UK; Royal Berkshire Hospital, Reading, UK; Royal Bournemouth Hospital, Bournemouth, UK; Guy’s and St Thomas’ NHS Trust, London, UK; and St George’s Hospital, London, UK. Informed consent was waived or was obtained according to national legislation, in line with the Helsinki declaration.
: Not applicable.
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other authors declare that they have no conflict of interest.
